Search Results - ia2xxx

3 Results

Sort By:

Diisocyanate Specific Monoclonal Antibodies for Occupational and Environmental Monitoring of Polyurethane Production Exposure-related Asthma and Allergy and Clinical Diagnosis

CDC researchers have developed monoclonal antibodies useful as diagnostics for diisocyanate (dNCO) exposure and for toxicity characterization of specific dNCOs. Currently, dNCOs are used in the production of all polyurethane products and are the most commonly reported cause of occupational-induced asthma and also linked to allergic contact dermatitis....

Published: 7/25/2024 | Inventor(s): Donald Beezhold, Tinashe Ruwona, Detlef Schmechel, Victor Johnson, Paul Siegel

Keywords(s): AAXXXX, AC5XXX, ACXXXX, AE2AXX, AE2CXX, AE2XXX, AE3XXX, AEXXXX, CDC Docket Import, CDC Docket Import CDC Prosecuting, Compositions, CONJUGATES, IA2XXX, IA3XXX, IA5XXX, IAXXXX, IDXXXX, Isocyanate, IXXXXX, Methods, NIOSH-HELD, Relating, VPXXXX, WCXXXX, WFXXXX, WGXXXX, WIXXXX, WJXXXX, WMXXXX, XAXXXX, XCXXXX, XIXXXX, YAXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, ResearchProducts > Antibodies, Application > Diagnostics, Application > Research Materials, Application > Occupational Safety and Health, Application > Therapeutics, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, TherapeuticArea > Oncology, TherapeuticArea > Ophthalmology, TherapeuticArea > Endocrinology, TherapeuticArea > Dental, Application > Consumer Products, TherapeuticArea > Pulmonology, TherapeuticArea > Cardiology, TherapeuticArea > Dermatology

Generation of Artificial Mutation Controls for Diagnostic Testing

This technology relates to a method of generating artificial compositions that can be used as positive controls in a genetic testing assay, such as a diagnostic assay for a particular genetic disease. Such controls can be used to confirm the presence or absence of a particular genetic mutation. The lack of easily accessible, validated mutant controls...

Published: 7/25/2024 | Inventor(s): Laurina Williams

Keywords(s): AA1XXX, AA5XXX, AA6XXX, AAXXXX, ARTIFICIAL, AXXXXX, CA1AXX, CA1CXX, CA1XXX, CAXXXX, controls, CXXXXX, diagnostic, GAXXXX, GCXXXX, GXXXXX, IA1BXX, IA2XXX, IA3XXX, IA5XXX, IAXXXX, IXXXXX, MUTATION, NA2XXX, OA2XXX, TESTING, VPXXXX, WBXXXX, WHXXXX, WIXXXX, WMXXXX, XBXXXX, XCXXXX, XEXXXX, YAXXXX, YBXXXX

Category(s): Collaboration Sought > Licensing, Application > Software / Apps, Application > Diagnostics, TherapeuticArea > Dermatology, TherapeuticArea > Immunology, TherapeuticArea > Pulmonology, Application > Research Materials, TherapeuticArea > Ophthalmology, TherapeuticArea > Dental, Application > Therapeutics, TherapeuticArea > Endocrinology, Application > Consumer Products, TherapeuticArea > Oncology, TherapeuticArea > Neurology, ResearchProducts > Computational models/software, TherapeuticArea > Cardiology, TherapeuticArea > Infectious Disease

Antagonist of A3 Adenosine Receptor Fluorescent Probes for the Study of Diseases that Involve A3 Signaling

This molecular probe may serve as a companion tool to identify and stratify patient populations based on the prevalence of the target A3 adenosine receptors. Small molecule drugs, A3AR-selective agonists, are currently in advanced clinical trials for the treatment of hepatocellular carcinoma, autoimmune inflammatory diseases, such as rheumatoid arthritis,...

Published: 7/25/2024 | Inventor(s): Kenneth Jacobson

Keywords(s): A3, ADENOSINE, ANTAGONISTS, BINDING, CA1CXX, CA1XXX, CAXXXX, CXXXXX, fluorescent, IA2XXX, IA3XXX, IAXXXX, IXXXXX, Molecular, Novel, Probes, RECEPTOR

Category(s): Collaboration Sought > Licensing, Application > Research Materials, Application > Diagnostics, TherapeuticArea > Dermatology, Application > Therapeutics, TherapeuticArea > Immunology, TherapeuticArea > Oncology